多药耐药基因蛋白P-gp和ABCG2在喉癌等头颈肿瘤中的作用及相关信号通路

doi:10.6040/j.issn.1673-3770.0.2015.469

摘要/Abstract

摘要： 喉癌作为恶性实体肿瘤,化学药物疗法在其综合治疗中扮演着日益重要的角色,但多药耐药(MDR)的产生成为导致化疗失败的主要原因。研究表明,多药耐药基因蛋白P-gp和ABCG2在喉癌的MDR中起着重要作用,P-gp和ABCG2之间或正或负呈相关性,其相关信号通路(MAPK)与P-gp和ABCG2在肿瘤中的表达也有一定的相关性,但其调控因素及如何由此提高化疗效果有待进一步研究。

关键词: ABCG2, P-gp, 多药耐药, 喉肿瘤

Abstract: Laryngocatcinoma is a type of malignant solid tumor, and chemotherapy plays an increasingly important role in its treatment, but multidrug resistance(MDR)has become the leading cause of chemotherapy failure. Researches have showed that P-gp and ABCG2 proteins are important in the MDR of laryngocatcinoma, P-gp may be positively or negatively correlated with ABCG2, and their related signal pathways(MAPK)are related to their expressions in tumors. However, how P-gp and ABCG2 are controlled and how to improve the effect of chemotherapy remain to be further investigated.

Key words: ABCG2, Multidrug resistance, Laryngeal cancer, P-gp

中图分类号:

R739.65

苏甜甜,张佳,孙臻峰. 多药耐药基因蛋白P-gp和ABCG2在喉癌等头颈肿瘤中的作用及相关信号通路[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 103-106.

SU Tiantian, ZHANG Jia, SUN Zhenfeng. Roles of multidrug resistance proteins P-gp and ABCG2 in laryngocatcinoma and their related signal pathways.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 103-106.

参考文献

[1] Wang X B, Wang S S, Zhang Q F, et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells[J]. Oncol Rep, 2010, 23(1):211-215.
[2] Biedler J L, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies[J]. Cancer Res, 1970, 30(4):1174-1184.
[3] Juliano R L, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochim Biophys Acta,1976, 455(1):152-162.
[4] 李圆, 吴正虎, 周雪华, 等. 四种耐药基因蛋白在喉癌组织中的表达及临床意义[J]. 浙江医学, 2010, 32(9):1333-1335. LI Yuan, WU Zhenghu, ZHOU Xuehua, et al. Expression of multidrug resistance proteins in laryngocatcinoma and its clinical significance[J]. Zhejiang Med J, 2010, 32(9):1333-1335.
[5] 杨征, 黄志刚, 钟琦, 等. 喉癌中p53与MDR1及MRP表达的相关性研究[J]. 中国耳鼻咽喉头颈外科, 2008, 15(5):289-292. YANG Zheng, HUANG Zhigang, ZHONG Qi, et al. Relationship between expression of p53 and MDRl, MRP in laryngeal cancer[J]. Chin Otolaryngol Otolaryngol Head Neck Surg, 2008, 15(5):289-292.
[6] Li L, Jiang A C, Dong P, et al. The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol[J]. Otolaryngol Head Neck Surg, 2007, 137(4):659-664.
[7] Li L, Jiang A C, Dong P, et al. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol[J]. Ann Surg Oncol, 2009, 16(5):1421-1428.
[8] Chen J S, Pardo F S, Wang-Rodriguez J, et al. EGFR regulates the side population in head and neck squamous cell carcinoma[J]. Laryngoscope, 2006, 116(3):401-406.
[9] Lopez J P, Wang-Rodriguez J, Chang C, et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines[J]. Arch Otolaryngol Head Neck Surg, 2007, 133(10):1022-1027.
[10] Tsunoda S, Okumura T, Ito T, et al. ABCG2 expression is an independent unfavorable prognostic factor in Esophageal squamous cell carcinoma[J]. Oncology-Basel, 2006, 71(3-4):251-258.
[11] Wang J, Guo L P, Chen L Z, et al. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line[J]. Cancer Res, 2007, 67(8):3716-3724.
[12] Chu T S, Chen J S, Lopez J P, et al. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma[J]. Arch Otolaryngol Head Neck Surg, 2008, 134(9):979-984.
[13] 沈斌, 董频. 乳腺癌耐药蛋白结构、功能及其在人体肿瘤中作用的研究进展[J]. 山东大学耳鼻喉眼学报, 2011, 25(3): 28-33. SHEN Bin, DONG Pin. Advances in breast cancer resistance protein structure, function and its role in human tumors[J]. J Otolaryngol Ophthalmol Shandong Univ, 2011, 25(3): 28-33.
[14] 沈斌, 董频, 英信江, 等. ABCG2及NF-κB p65在下咽癌中的表达意义[J]. 山东大学耳鼻喉眼学报, 2012, 26(4):17-20. SHEN Bin, DONG Pin, YING Xinjiang, et al. Expressions and implication of ABCG2 and NF-κB p65 in hypopharyngeal cancer[J]. J Otolaryngol Ophthalmol Shandong Univ, 2012, 26(4):17-20.
[15] Krishnamurthy P, Schuetz J D. Role of ABCG2 BCRP in biology and medicine[J]. Arm Rev Pharmacol Toxicol, 2006, 46(2):381-410.
[16] 史博. 胰腺癌中ABCG2和P-gp的表达及意义[D]. 中国医科大学, 2010.
[17] Cisternino S, Mercier C, Bourasset F, et al. Expression, up-regulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier[J]. Cancer Res, 2004, 64(9):3296-3301.
[18] Stein U, Walther W, Lemm M, et al. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo[J]. Int J Cancer, 1997, 72:885-891.
[19] Bark H, Xu H D, Kim S H, et al. P-glycoprotein down-regulates expression of breast cancer resistance protein in a drug-free state[J]. FEBS Letters, 2008, 582(17): 2595-2600.
[20] Poller B, Drewe S, Krahenbuhl S, et al. Regulation of BCRP(ABCG2)and P-glycoprotein(ABCB1)by cytokines in a model of the human blood-brain barrier[J]. Cell Mol Neurobiol, 2010, 30(1):63-70.
[21] Trock B J, Leonessa F, Clarke R. Multidrug resistance and breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance[J]. J Natl Cancer Inst, 1997, 89(13):917-931.
[22] 孙臻峰, 沈斌, 苏甜甜, 等. 耐药基因MDR1(P-gp)和ABCG2在Hep-2细胞耐药中的作用研究[J]. 临床耳鼻咽喉头颈外科杂志, 2015, 29(11):1016-1020. SUN Zhenfeng, SHEN Bin, SU Tiantian, et al. The study of the interaction of MDR1(P-gp)and ABCG2 in Hep 2 cells[J]. Clin J Otorhinolarynol Head Neck Surg, 2015, 29(11):1016-1020.
[23] Carpenter G, Cohen S. Epidermal growth factor[J]. Annu Rev Biochem, 1979, 48(7):193-216.
[24] Shi Z, Peng X X, Kim I W, et al. Erlotinib(Tarceva, OSI-774)antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance[J]. Cancer Res, 2007, 67(22):11012-11020.
[25] Dai C L, Tiwari A K, Wu C P, et al. Lapatinib(Tykerb, GW572016)reverses multidrug resistance in cancer cells by inhibiting the activity of ATP binding cassette subfamily B member 1 and G member 2[J]. Cancer Res, 2008, 68(19):7905-7914.
[26] Graber-Maier A, Gutmann H, Drewe J. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib[J]. Mol Pharm, 2010, 7:1618-1628.

相关文章 15

[1]	文锋,张驰,扈希昊,董冰婉,秦永,赵恩民. 喉部腺样囊性癌4例并文献复习[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 119-125.
[2]	毛泽凡陈曦,程雷. 喉神经内分泌癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 114-119.
[3]	王媚李志海. 喉癌干细胞:克服多药耐药性的潜在治疗靶点[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 120-128.
[4]	李晓明. 喉癌治疗中喉功能保留的历史、现状和未来[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 1-5.
[5]	刘鸣. 早期声门癌的内镜治疗[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 6-9.
[6]	黄若飞,陈立晓,陈歆维,於子卫,金斌,祝江才,董频. 喉异期喉重复癌[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 36-39.
[7]	孙笑晗,李娜. 喉保留策略在喉癌治疗中的应用—美国临床肿瘤学会临床实践指南更新(2017)介绍[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 40-42.
[8]	丁洁,孙彦. 142例喉癌术后患者整体睡眠质量状况调查分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 76-81.
[9]	张小平,杨登权,王少新,黄小明. 连续性院外管理对喉癌患者术后生活质量的影响[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 169-174.
[10]	陈慧君,宋圣花,周涵,董伟达,乔明哲,陈曦,徐进,林子萍,邢光前. 血小板与淋巴细胞比值对喉癌复发的预测价值[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 106-110.
[11]	冯剑,周涵,董伟达. 喉癌内镜诊断技术研究进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 129-133.
[12]	姚慧,万文锦. 同伴支持教育在全喉切除术后患者延续护理中的应用效果分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 138-142.
[13]	邹良玉,李连贺,岳文慧,韩志鹏,张子惠. MIF、GSK-3β在喉鳞状细胞癌中表达的临床意义及相关性研究[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 76-80.
[14]	陈立晓,蒋锐,於子卫. 窄带成像技术在咽喉肿瘤诊治中的应用[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 104-108.
[15]	张明德,张祖平,于学民,魏燕红,袁英. RASSF2A基因甲基化在喉癌组织中的表达及意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 64-67.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed